Teva is pleased with the US FDA's approval of its generic versions of EpiPen® and EpiPen Jr ® (epinephrine injection, USP) Auto-Injectors in the US.
"Today's approval marks an important step forward in bringing patients an additional epinephrine auto-injector option and furthers our commitment to accessibility to quality products for the patients who need them," said Brendan O'Grady, Executive Vice President, North America Commercial.
The company is applying its full resources to this important launch in the coming months and is eager to begin supplying the market.
Teva Pharmaceutical Industries Ltd.
Kevin C. Mannix, 215-591-8912
Ran Meir, 215-591-3033
Tomer Amitai, 972 (3) 926 7656
Kelley Dougherty, 973-658-0237
Elizabeth DeLuca, 267-468-4329
Yonatan Beker, 972 (54) 888 5898